Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Striking Cancer With Its Own Weapon: Metastasizing Cells!

Striking Cancer With Its Own Weapon: Metastasizing Cells!

The 10 hallmarks of cancerinclude migration to different tissues and organs, or metastasis as this process. Cancer cells can return to the primary tumor after migrating elsewhere, as previously discovered. Recently, using these cells as carriers to deliver drugs to the primary tumor has attracted attention. In July 2018, Science Translational Medicinepublished a study that, by programming returning cancer cells with CRISPR gene editing, extended survival in mouse brain cancer models.

Cancer cells return to the primary tumor after migrating to other tissues and organs. Discovered 12 years ago, this may be one of the most surprising, unexpected developments. Self-seeding is the name of this phenomenon, which has inspired treatment strategies such as adding to these cells oncolytic (cancer-killing) viruses or suicide genes to target cancer cells at the primary tumor site.

Researchers first removed tumor cells from mice. Using CRISPR gene editing, they added molecules enabling death receptor binding. The cells could thus bind other cancer cells carrying death receptors and trigger apoptosis (programmed cell death). They were reinjected into mice with 3 tumor types: glioblastoma (GBM), recurrent glioblastoma, and breast cancer metastatic to the brain.

According to the Results;

  • The treatment significantly increased mouse survival.
  • Mice with primary or recurrent brain tumors showed substantial shrinkage after treatment. Of mice, 90 percent survived for months afterward.
  • CRISPR-modified cells also received a drug target allowing drugs to eliminate them safely after treatment.

What Does This Study Mean for Us?

  • Despite great promise, challenges remain. CRISPR-modified cancer cells attack the primary site directly, but cancer can metastasize to many organs. This treatment cannot target those other metastases.
  • Another issue is that modified cancer cells could form new tumors. They remain cancer cells, after all.
  • This method may be especially effective in oligometastatic cancers (with few metastases).
  • It must be emphasized that these studies were performed in the laboratory and need confirmation through further analyses and clinical trials.

Sources

Clemens Reinshagen, Deepak Bhere, Sung Hugh Choi, Stefan Hutten, Irina Nesterenko, Hiroaki Wakimoto.
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.
Science Translational Medicine, 11 Jul 2018.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Striking Cancer With Its Own Weapon: Metastasizing Cells!

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy